With the rising prevalence of chronic diseases and growth of biologics, MC Pro recommends holding Gland Pharma. Post the recent correction and downward adjustments in estimates, Gland Pharma is trading at 17x EV/EBITDA for FY24e. Here’s why it makes for a good investment bet.
first published: Jun 23, 2022 07:19 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
Nifty’s Move Hinges On RBI Rate Decision; HUL, ITC Hotels In Focus| Opening Bell Live
Nifty Sideways But Holds 26,000 Ahead Of MPC Rate Decision| IT & Realty Upbeat| Closing Bell Live
Is it a good time to enter Bajaj Finance post Q3 business update? | Opening Bell
Attractive valuation, strong earnings potential: Buy this stock for the long term | Ideas for Profit
Vesuvius India made fresh lifetime high. Right time to buy the stock or wait for a drop?
Indian Hotel Industry Sees Strong Demand; Buy This Stock For Sector Upcycle | Ideas For Profit
Can strong auto demand drive this company’s stock further? | Ideas For Profit
